Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: David M. Gloss who wrote (4636)	11/17/1999 9:15:00 AM
From: KAKALAK	Respond to of 4891

A BIG biotech will infuse millions into ADVR and take a number of shares in the process. To put is simply, for the SI board, a Merck or Pfizer type bohemoth will infuse 20 mil into ADVR and take 40 mil shares for their trouble (share value of .50). Bingo, suddenly a key player says ADVR is worth .50/share. If Merck says its worth .50, why not .75 or 1.00? The momentum and Merck's blessing will carry the price well beyond .50

To: David M. Gloss who wrote (4636)	11/17/1999 1:13:00 PM
From: OLD JAKE JUSTUS	Read Replies (2) \| Respond to of 4891

What do we hear about Argentina and ADVR? My personal opinion, is that if they are going to depend on approval of the FDA to commercialize Product R, (Reticulose), then we will have a long and expensive wait coming. I hardly think, although anything is possible, and possibly probable, but I doubt if any company, in their right mind, would infuse a lot of funds into ADVR until the Ind is issued. Then, they may still want to wait for the approval of R for human consumption. This is my opinion, and of course, I could be totally wrong.